This invention provides a compound having the structure ##STR00001## wherein A is a ring structure, with or without substitution; Z is present or absent and when present is ##STR00002## wherein n is 0, 1, 2, 3, or 4; Y is (CR.sub.11R.sub.12), NH(CR.sub.11R.sub.12), or O(CR.sub.11R.sub.12), wherein R.sub.11 and R.sub.12 are each hydrogen or combine to form a carbonyl; R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are independently H, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heteroaryl, hydroxyl, amino, ester or amide; represents a bond, which is present or absent and when is present, then R.sub.7 and R.sub.8 are absent; R.sub.7 and R.sub.8 are present when is absent and are independently H, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heteroaryl, hydroxyl, amino, ester, amide or R.sub.5 and R.sub.7 combine to form a carbonyl or R.sub.6 and R.sub.8 combine to form a carbonyl; R.sub.9 and R.sub.10 are each hydrogen or combine to form a carbonyl; and when is present, Z is ##STR00003## where n=1, Y is (CR.sub.11R.sub.12) where R.sub.11 and R.sub.12 are H, A is unsubstituted indole attached at the 3-position of the indole, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.9 and R.sub.10 are each H, and one of R.sub.1 or R.sub.2 is H, then the other one of R.sub.1 or R.sub.2 is other than H or ethyl,
or a pharmaceutically acceptable salt, diastereomer, or enantiomer thereof.

This invention provides a compound having the structure ##STR00001## wherein A is a ring structure, with or without substitution; Z is present or absent and when present is ##STR00002## wherein n is 0, 1, 2, 3, or 4; Y is (CR.sub.11R.sub.12), NH(CR.sub.11R.sub.12), or O(CR.sub.11R.sub.12), wherein R.sub.11 and R.sub.12 are each hydrogen or combine to form a carbonyl; R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are independently H, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heteroaryl, hydroxyl, amino, ester or amide; represents a bond, which is present or absent and when is present, then R.sub.7 and R.sub.8 are absent; R.sub.7 and R.sub.8 are present when is absent and are independently H, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heteroaryl, hydroxyl, amino, ester, amide or R.sub.5 and R.sub.7 combine to form a carbonyl or R.sub.6 and R.sub.8 combine to form a carbonyl; R.sub.9 and R.sub.10 are each hydrogen or combine to form a carbonyl; and when is present, Z is ##STR00003## where n=1, Y is (CR.sub.11R.sub.12) where R.sub.11 and R.sub.12 are H, A is unsubstituted indole attached at the 3-position of the indole, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.9 and R.sub.10 are each H, and one of R.sub.1 or R.sub.2 is H, then the other one of R.sub.1 or R.sub.2 is other than H or ethyl,
or a pharmaceutically acceptable salt, diastereomer, or enantiomer thereof.

The invention discussed in this application relates to hydroxamic acid-based compounds that are useful as imaging agents when bound to an appropriate metal centre, particularly for the imaging of tumours.

The invention discussed in this application relates to hydroxamic acid-based compounds that are useful as imaging agents when bound to an appropriate metal centre, particularly for the imaging of tumours.

The present disclosure provides substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes, of Formula I

D-M-D (Formula I)

useful as antiviral agents. In certain embodiments disclosed herein M is a group P-A-P where A is

##STR00001##

Certain substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. Pharmaceutical compositions/and combinations containing one or more substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes and a pharmaceutically acceptable carrier are also provided by this disclosure. Methods for treating viral infections, including Hepatitis C viral infections are provided by the disclosure.

The present disclosure provides substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes, of Formula I

D-M-D (Formula I)

useful as antiviral agents. In certain embodiments disclosed herein M is a group P-A-P where A is

##STR00001##

Certain substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. Pharmaceutical compositions/and combinations containing one or more substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes and a pharmaceutically acceptable carrier are also provided by this disclosure. Methods for treating viral infections, including Hepatitis C viral infections are provided by the disclosure.

The present disclosure provides substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes, of Formula I
D-M-D(Formula I)
useful as antiviral agents. In certain embodiments disclosed herein M is a group P-A-P where A is ##STR00001##
Certain substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. Pharmaceutical compositions/and combinations containing one or more substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes and a pharmaceutically acceptable carrier are also provided by this disclosure. Methods for treating viral infections, including Hepatitis C viral infections are provided by the disclosure.

The present disclosure provides substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes, of Formula I
D-M-D(Formula I)
useful as antiviral agents. In certain embodiments disclosed herein M is a group P-A-P where A is ##STR00001##
Certain substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. Pharmaceutical compositions/and combinations containing one or more substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes and a pharmaceutically acceptable carrier are also provided by this disclosure. Methods for treating viral infections, including Hepatitis C viral infections are provided by the disclosure.

The present disclosure provides substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes, of Formula I

D-M-D(Formula I)

useful as antiviral agents. In certain embodiments disclosed herein M is a group -P-A-P- where A is

##STR00001##

Certain substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. Pharmaceutical compositions/and combinations containing one or more substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes and a pharmaceutically acceptable carrier are also provided by this disclosure. Methods for treating viral infections, including Hepatitis C viral infections are provided by the disclosure.

Stable noribogaine salt ansolvates are useful for preparing pharmaceutical compositions and for alleviating nociceptive pain in a patient. Such ansolvates can be prepared by slurrying solvated forms, preferably MeOH solvated noribogaine hydrochloride in EtOH/water.